PHC Holdings (6523) · InitiativeAchieved
Strengthening drug discovery support operations through the acquisition of LSSI as a subsidiary and the integration of clinical trial operations
First written in FY2024-Q1. 1 of 2 entries say "Achieved", first in FY2024. Latest entry: FY2024.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Strengthening drug-discovery support functions through the creation of LSSI as a subsidiary and integration of the clinical-trial businessA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2024AchievedAnnual report
「On 1 November 2023, the LSIM clinical-trials business was transferred through an absorption-type company split to 株式会社LSIM安全科学研究所, a subsidiary of LSIM, and all shares in LSSI were acquired from LSIM, making LSSI our subsidiary. LSSI's corporate name was changed to メディフォード株式会社.」
The acquisition of all shares in LSSI and the transfer of the clinical-trials business were completed as scheduled, completing the creation of a subsidiary and business integration under the name メディフォード株式会社. - FY2024-Q1First statedAnnual report
「We aim to capture business opportunities and achieve further growth by acquiring all shares in LSSI from LSIM and making LSSI our subsidiary. Through this integration, we will advance the following initiatives.」
The company announced plans to acquire all shares in LSSI and transfer the LSIM clinical-trials business on 1 November 2023, while strengthening analytical technologies for increasingly diverse modalities, capabilities for supporting overseas clinical trials, and partnerships with pharmaceutical companies, ventures and academia.